Table 2 Characteristics of the 33 trials with adequate reporting of serious adverse events
Characteristic | n (%) |
|---|---|
n = 33 | |
Study phase | |
III | 29 (88) |
IV | 4 (12) |
Study design | |
Parallel groups | 31 (94) |
Cross-over | 2 (6) |
No. of intervention groups | |
2 | 30 (91) |
3 | 3 (9) |
Primary funding source | |
Industry | 27 (82) |
US National Institutes of Health | 2 (6) |
US federal funding | 1 (3) |
Other | 3 (9) |
Medical condition | |
Endocrinology | 6 (18) |
Infectious diseases | 4 (12) |
Cardiology | 3 (9) |
Gynecology | 3 (9) |
Neurology | 3 (9) |
Rheumatology | 3 (9) |
Psychiatry | 3 (9) |
Other | 8 (24) |
Study location | |
At least one site in the United States | 24 (73) |
No site in the United States | 9 (27) |
Type of journal | |
Specialty | 24 (73) |
General | 9 (27) |
ClinicalTrials.gov NCT reported in article | |
Yes | 27 (82) |
No | 6 (18) |